28Mar 2018

THE POLYMORPHISM OF TUMOR NECROSIS FACTOR ALPHA AND HEPATITIS C VIRUS RELATED HCC.

  • Department of Clinical and Chemical Pathology, Kasr Al Aini,-Cairo University, Cairo-Egypt.
  • Department of Hematology, Theodor Bilharz Research Institute, Cairo-Egypt.
  • Department of Tropical Medicine, Kasr Al Aini-Cairo University, Cairo-Egypt.
  • Department of Tropical Medicine, Theodor Bilharz Research Institute, Cairo-Egypt.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Liver cancer is the second leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is the most common type of primary malignant liver tumor. Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, cirrhosis, and hepatocellular carci?noma throughout the world. Hepatitis C virus (HCV) infection is a major public health burden in Egypt. Proinflammatory cytokines as TNF-α were reported to be elevated among hepatitis patients. TNF-α has been implicated in liver development and regeneration but may also contribute to the pathogenesis of liver-related diseases such as cirhossis, fibrosis, and cancer. Aim of the work: The aim of the present study is to determine the genotypes and alleles fre-quencies of TNF-α 308 G/A polymorphisms among some of the Egyptian patients with chronic HCV infection and healthy individuals to assess whether these genes are involved in chronic HCV susceptibility and/or HCC development. Material and methods: A total of 55 HCV, 60 HCC and 50 healthy subjects were enrolled in the study for evaluation. Genomic DNA was extracted from the peripheral blood and genotyping was performed using Real Time polymerase chain reaction (RT- PCR) methodology. Results: G/A, G/G and A/A frequencies in HCV patients were 20.0%%, 63.6%%, 16.4%% respectively, furthermore the frequencies were 10.0%, 90.0%, 00.0% in HCC patients and 8.0%, 88.0%, 4.0% in the control group respectively. The frequencies of G and A alleles in HCV patients were 73.7%, 26.3% and in HCC patients were 95.0%, 5.0% while in the control group the frequencies were 92.0%, 8.0% respectively. There was A significant difference between the studied groups regarding G/A, G/G, A/A frequencies. There was a significant difference in allele frequencies between patients with HCV and control groups (p=0.01). Moreover, there was highly significant difference in allele frequencies between HCC and HCV groups (p=0.001). While there was no significant difference in allele frequencies between HCC and control groups (p=0.2). Conclusion: The present study showed that TNF-α 308 G /A polymorphism was associated with increased HCC risk in Egyptian HCV infected population.


  1. Caglevic C,Silva S,?Mahave M,?Torres J,?Rolfo C,?Gallardo J and et al (2016) ."Hepatocellular carcinoma in identical twins in Chile: case report".E cancer medical science.? 21; 10:708.
  2. Holah N, El-Azab D, Aiad H and Sweed D (2015). "Hepatocellular carcinoma in Egypt: epidemiological and histopathological properties". Menoufia Medical Journal 28:718.
  3. IyerHYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Iyer%20P%5BAuthor%5D&cauthor=true&cauthor_uid=19818350" P, Zekri A, Hung C, Schiefelbein E, Ismail K, Hablas A, et al(2010)." Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients". Experimental and molecular pathology. 88 (1):107-111.
  4. Ezzat S, Abdel-Hamid M, Eissa S, Mokhtar N,Labib N,?El-Ghorory L, et al (2005). "Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt". International Journal of Hygiene and Environmental Health.208:329.
  5. Kandeel A, Genedy M, El-Refai S, Funk A, Fontanet A and Talaat M (2017). "The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment". Liver International. 37: 45?53.
  6. De Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani? M, Monno A, et al (2004)." Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progressionin chronic viral hepatitis". Journal of Immunology. 173, 1417?1425.
  7. Dondeti M, El-Maadawy E, and? Talaat R (2016). "Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms".? World Journal of Gastroenterol? 22(30): 6800?6816.
  8. Banday? M, Balkhi? H, Hamid Z, Sameer A, Chowdri N, Haq E (2016).?"Tumor necrosis factor-α (TNF-α)-308G/A promoter polymorphism in colorectal cancer in ethnic Kashmiri population ? A case control study in a detailed perspective" .Meta Gene.? 9: 128-136.
  1. Qin H, Liu B, Shi T, Liu Y, Sun Y and Ma Y(2010). "Tumour Necrosis Factor-α Polymorphisms and Hepatocellular Carcinoma: a Meta-analysis". The Journal of International Medical Research. 38: 760 ? 768.
  2. Patio-Garcia A, Sotillo-Pieiro E, Modesto C and ?Sierrases-Maga L (2000). "Analysis of the human tumour necrosis factoralpha (TNFα) gene promoter poly morphisms in children with bone cancer".Journal of Medical Genetics.37(10):789-92.
  3. Akkiz H, Bayram S, Bekar A, et al (2009)." G-308A TNF- α polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case?control study". Cancer Epidemiology; 33: 261 ? 264.
  4. Herbst A. and Reddy K (2012)." Risk factors for hepato-cellular carcinoma. " Clinical Liver Disease. 1 (6): 180-182.
  5. Galbraith JW, Donnelly JP, Franco RA, Overton ET, Rodgers JB, Wang HE (2014)National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States. CID. 9;59 (6):755-64.
  6. Coussens L and Werb Z (2002). "Inflammation and cancer". Nature.420: 860-867.
  7. Koziel M(1999). "Cytokines in viral hepatitis".Seminars in Liver Diseases. 19(2):157-69.
  8. Kirkpatrick A, Bidwell J, van den Brule A, Meijer CJ, Pawade J, Glew S (2003). "TNFalpha polymorphism frequencies in HPV-associated cervical dysplasia".Gynecologic Oncology.92(2):675?679.
  9. Cha C and De Matteo R (2005). "Molecular mechanisms in hepatocellular carcinoma development". Best Practice & Research Clinical Gastroenterology . 19: 25- 37.
  10. Chuang E, Del Vecchio A, Smolinski S, Song X and Sarisky R (2004). "Biomedicines to reduce inflammation but not viral load in chronic HCV: what the sense". Trends Biotechnol .22(10):517-523.
  11. Levrero M (2006). Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene(2006)?25,?3834?3847.
  12. Feng H, Kuai J, Zhang M, Wang G, Shi Y and Zhang J(2014)." Tumor necrosis factor-alpha gene −308G > A polymorphism alters the risk of hepatocellular carcinoma in a Han Chinese population." Diagnostic Pathology. 9:199.
  13. Talaat R, Esmail A, Elwakil R, Gurgis A, Nasr M (2012)." Tumor necrosis factoralpha -308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients". Chineese Journal of Cancer . 31(1):29- 35.
  14. Jeng J,Tsai J,Chuang L, Ho M, Lin Z ,Hsieh M ,et al (2007)." Tumor Necrosis Factor-A 308.2 Polymorphism Is Associated with Advanced Hepatic Fibrosis and Higher Risk for Hepatocellular Carcinoma ". Neoplasia . Vol. 9, No. 11, pp. 987 ? 992.
  15. Tavakolpour S and Sali S (2016)." Tumor Necrosis Factor‐α‐308 G/A Polymorphisms and Risk of Hepatocellular Carcinoma: A Meta‐Analysis. Hepatitis Monthly". 16(4): e33537.
  16. Romero-Go?mez M, Montes-Cano M, Otero-Ferna?ndez M, Torres B,Sa?nchez-Mun?oz D,Aguilar F , et al (2004). "SLC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C".Gut 2004;53:446?450.
  17. Qing Sun, Xuedan Guo, Qi Wang, Fan Zhao (2016). The association of TNF-308 (G/A) gene polymorphisms and hepatocellular carcinoma risk: a meta-analysis. Chin J Cancer Res 2016;28 (5):536-542.
  18. Constantini P,Wawrzynowicz-Syczewska M, Michael C ,Boron-Kaczmarska A, McFarlane I, et al (2002). "Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy". Liver. Volume 22, Issue 5 October 2002?Pages 404?412.

[Mona Salah, Bothina Madkou, Rabab Fouad, Faiza El-Essawy, khaled Tawfeek, Tamer Mahmoud El-baz and Ayman Mohamed Abdel Aziz. (2018); THE POLYMORPHISM OF TUMOR NECROSIS FACTOR ALPHA AND HEPATITIS C VIRUS RELATED HCC. Int. J. of Adv. Res. 6 (Mar). 1140-1146] (ISSN 2320-5407). www.journalijar.com


Rabab Fouad
Theodor Bilhars Research Institute

DOI:


Article DOI: 10.21474/IJAR01/6776      
DOI URL: https://dx.doi.org/10.21474/IJAR01/6776